Key Points AbbVie continues to diversify its revenue streams with successful expansions in immunology and aesthetics. Bristol-Myers Squibb maintains high net margins while offering a significantly lower valuation than many industry peers. Which pharmaceutical heavyweight provides the most attractive balance of growth and value for your 2026 portfolio? 10 stocks we like better than AbbVie › Navigating the drug manufacturing world requires balancing patent cliffs against fresh pipelines. Choosing between AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) in 2026 involves weighing steady growth against deep value in a shifting landscape.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.